The recent approval of a drug for the treatment of endometriosis pain is shared in this story in a way that satisfies many of our review site criteria. The story is carefully written, with lots of detailed explanations of the drug’s potential benefits — and drawbacks.
Although some crucial information about funding and possible conflicts of interest is missing, the story otherwise affords the reader a readable and comprehensive “take” on the new drug. One clinical trial detail we think should have been included: The measured benefits for both the drug group and the placebo group.
Endometriosis, a condition in which tissue migrates from the uterus into the abdomen of women, is relatively common and can be debilitatingly painful. While there is no cure at present, efforts to control the pain include hormonal treatments and even surgery, which produce their own complications. This story describes a new non-hormonal drug that appears to avoid some—but not all—of those complications.
The story does a good job of describing the monthly cost ($850) for women who do not have health insurance. The inference is that insurers will cover the cost for others.
The story needed to include more information about the study results–in particular, how both the drug and the placebo performed in the trials.
As we learn from the NEJM study, the drug reduced pain for about half of the women who took it–but the placebo also reduced pain for about 35% of the women who took it. That’s a good detail to include as it provides a better sense of the drug’s effectiveness.
The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause.
The double-blind, placebo-controlled trials are described, as are cautions, such as the short-term nature of the research.
The reader will find ample information about the unpleasant symptoms of endometriosis. In some areas, it comes close to disease-mongering, when pointing out very rare instances of women needing many surgeries, or a case study of one woman having endometrial tissue in her nose. However, endometriosis is a medical condition, and often under-diagnosed, so we’ll rate this satisfactory.
The scientist who led the two trials is clearly identified as such, but his consulting relationship with the company now marketing the drug is not mentioned, nor is the fact that that company, now positioned to benefit from selling the drug, paid for the studies.
A number of existing pain-reduction alternatives are mentioned, from hormonal treatments to surgery, and their debits discussed. It would have been helpful to try and articulate how many women find the current alternatives insufficient.
The text offers a likely date when this just-approved drug would become available at pharmacies.
Although the research report describing the trials was published in The New England Journal of Medicine more than a year ago, this story is pegged to a more useful (to readers) “new event,” the US Food and Drug Administration’s approval of the drug.
Abbvie, the company that funded the Stage 3 clinical trials of elagolix (brand name: Orilissa) and will now market the drug, made available an extensive news release on its web site. The Vox story contains a good bit of enterprise reporting and produced a story that is far more clear than the company’s effort.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like